Evidence map›Paper›PMID 38613944›Full record

ArticleMolecular immunology2024

SHIP inhibition mediates select TREM2-induced microglial functions.

Gautham S Ramakrishnan, William L Berry, Angela Pacherille, William G Kerr, John D Chisholm, Chiara Pedicone, Mary Beth Humphrey

Open access · hybridAbstract read
In one paragraph

Article in Molecular immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Microglial phagocytosis in Alzheimer disease.Nature reviews. Neurology · 2026
    Review
  6. Roles of TREM2 in Alzheimer's disease.Translational neurodegeneration · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Gautham S RamakrishnanDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
William L BerryDepartment of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Stephenson Cancer Center, Oklahoma City, OK, USA.
Angela PacherilleDepartment of Chemistry, Syracuse University, Syracuse, NY, USA.
William G KerrDepartment of Chemistry, Syracuse University, Syracuse, NY, USA; Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, USA; Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY, USA.
John D ChisholmDepartment of Chemistry, Syracuse University, Syracuse, NY, USA.
Chiara PediconeDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mary Beth HumphreyDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Oklahoma City Veteran's Affairs Medical Center, Oklahoma City, OK, USA. Electronic address: MaryBeth-Humphrey@ouhsc.edu.
Syracuse University · USUniversity of Oklahoma Health Sciences Center · USIcahn School of Medicine at Mount Sinai · USOklahoma City VA Medical Center · USSUNY Upstate Medical University · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
Translating SHIP1 Genetics to Generate a Novel Alzheimers Pharmacologic AgentRF1AG059717 · NIA · UNIVERSITY OF KENTUCKY · PI ESTUS, STEVEN, HUMPHREY, MARY BETH · 2018 to 2019
$3.9M
NCI NIH HHS P30 CA225520NIA NIH HHS RF1 AG059717
6 · The paper itself

Abstract

Microglia play a pivotal role in the pathology of Alzheimer's Disease (AD), with the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) central to their neuroprotective functions. The R47H variant of TREM2 has emerged as a significant genetic risk factor for AD, leading to a loss-of-function phenotype in mouse AD models. This study elucidates the roles of TREM2 in human microglia-like HMC3 cells and the regulation of these functions by SH2-containing inositol-5'-phosphatase 1 (SHIP1). Using stable cell lines expressing wild-type TREM2, the R47H variant, and TREM2-deficient lines, we found that functional TREM2 is essential for the phagocytosis of Aβ, lysosomal capacity, and mitochondrial activity. Notably, the R47H variant displayed increased phagocytic activity towards apoptotic neurons. Introducing SHIP1, known to modulate TREM2 signaling in other cells, revealed its role as a negative regulator of these TREM2-mediated functions. Moreover, pharmacological inhibition of both SHIP1 and its isoform SHIP2 amplified Aβ phagocytosis and lysosomal capacity, independently of TREM2 or SHIP1 expression, suggesting a potential regulatory role for SHIP2 in these functions. The absence of TREM2, combined with the presence of both SHIP isoforms, suppressed mitochondrial activity. However, pan-SHIP1/2 inhibition enhanced mitochondrial function in these cells. In summary, our findings offer a deeper understanding of the relationship between TREM2 variants and SHIP1 in microglial functions, and emphasize the therapeutic potential of targeting the TREM2 and SHIP1 pathways in microglia for neurodegenerative diseases.

Indexed as

Membrane GlycoproteinsMicrogliaPhagocytosisPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesReceptors, ImmunologicAlzheimer DiseaseAmyloid beta-PeptidesAnimalsApoptosisCell LineHumansLysosomesMitochondriaSignal TransductionAmyloid beta-PeptidesINPP5D protein, humanMembrane GlycoproteinsPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesReceptors, ImmunologicTREM2 protein, humanAlzheimer’s diseaseMicrogliaPhagocytosisSHIP1SHIP inhibitorsTREM2

Identifiers

PMID38613944
PMCPMC11097602
OpenAlexW4394779446

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.